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and transcriptional silencing of lentiviruses  
in a context-specific, isoform-specific fashion
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Abstract 
Background: The promyelocytic leukemia (PML) protein, a type I interferon (IFN-I)-induced gene product and a 
member of the tripartite motif (TRIM) family, modulates the transcriptional activity of viruses belonging to various 
families. Whether PML has an impact on the replication of HIV-1 has not been fully addressed, but recent studies point 
to its possible involvement in the restriction of HIV-1 in human cells and in the maintenance of transcriptional latency 
in human cell lines in which HIV-1 is constitutively repressed. We investigated further the restriction of HIV-1 and a 
related lentivirus, SIVmac, by PML in murine cells and in a lymphocytic human cell line. In particular, we studied the 
relevance of PML to IFN-I-mediated inhibition and the role of individual human isoforms.
Results: We demonstrate that both human PML (hPML) and murine PML (mPML) inhibit the early post-entry stages 
of the replication of HIV-1 and a related lentivirus, SIVmac. In addition, HIV-1 was transcriptionally silenced by mPML 
and by hPML isoforms I, II, IV and VI in MEFs. This PML-mediated transcriptional repression was attenuated in presence 
of the histone deacetylase inhibitor SAHA. In contrast, depletion of PML had no effect on HIV-1 gene expression in a 
human T cell line. PML was found to contribute to the inhibition of HIV-1 by IFN-I. Specifically, IFN-α and IFN-β treat-
ments of MEFs enhanced the PML-dependent inhibition of HIV-1 early replication stages.
Conclusions: We show that PML can inhibit HIV-1 and other lentiviruses as part of the IFN-I-mediated response. The 
restriction takes place at two distinct steps, i.e. reverse transcription and transcription, and in an isoform-specific, cellu-
lar context-specific fashion. Our results support a model in which PML activates innate immune antilentiviral effectors. 
These data are relevant to the development of latency reversal-inducing pharmacological agents, since PML was pre-
viously proposed as a pharmacological target for such inhibitors. This study also has implications for the development 
of murine models of HIV-1.
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Background
In mammals, many effectors are involved in the innate 
immune response to pathogens, including viruses. Of par-
ticular interest are restriction factors that are members of 
the tripartite motif (TRIM) protein superfamily. Several 
of the TRIM superfamily members are upregulated by 
IFN-I, suggesting that they might be involved in antivi-
ral innate immunity (reviewed in [1]). PML, also known 
as TRIM19, is a member of this family of proteins. PML 
was initially identified as part of a hybrid protein that also 
contains retinoic acid receptor α (RARα) and that causes 
acute promyelocytic leukemia [2–4]. PML is expressed 
in all cell lines tested [5] and localizes to the nucleus; it 
is found both in the nucleoplasm and in association with 
a nuclear multiprotein structure called the nuclear body 
(NB) [6, 7]. In addition to PML, NBs include several other 
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proteins, but the integrity of this structure depends on 
the presence of PML [8]. The transcription of some PML 
NB proteins, including PML and Sp100, is upregulated by 
interferons [5, 9, 10] and contributes to cellular defense 
mechanisms [11].
The interactions between PML (or PML NBs) and 
viruses have been well documented. Soon after the dis-
covery of PML NBs, Maul and colleagues showed that 
herpes simplex virus type 1 (HSV-1) causes the cellu-
lar redistribution of PML from PML NBs [12]. Further 
investigations demonstrated that the HSV-1 immediate-
early (IE) gene product ICP0 localizes to and disrupts 
PML NBs, resulting in an increase in viral gene expres-
sion [13]. In human cytomegalovirus (HCMV)-infected 
cells, the PML NB-associated protein Daxx (Death 
domain-associated protein) silences viral immediate-
early gene expression, but this antiviral mechanism is 
counteracted by the HCMV protein pp71 [14, 15]. It has 
also been reported that constitutive overexpression of 
PML in mouse cells induces resistance to infection by 
RNA viruses, such as vesicular stomatitis virus (VSV) 
and influenza A [16]. Furthermore, IFN-induced over-
expression of PML in wild-type (WT) mouse embryonic 
fibroblasts (MEFs) represses the transcription of human 
foamy virus (HFV), a retrovirus, by forming a complex 
with the HFV transactivator, Tas, thereby preventing 
the direct binding of Tas to viral DNA [17]. Accord-
ingly, this inhibitory mechanism is not observed in PML 
knockout (KO) cells. In contrast to the antiviral activi-
ties often associated with PML, it was recently shown 
that depleting PML reduces the production of infectious 
hepatitis C virus particles, indicating that PML may 
enhance virus particle production [18]. Likewise, estab-
lishment of human papillomavirus (HPV) is enhanced 
by PML expression in the early part of the life cycle [19]. 
Whether PML modulates the permissiveness to HIV-1 
and other lentiviruses has been controversial [20, 21], 
but recent reports have converged toward an inhibitory 
role for PML [22, 23].
Although antiretroviral therapy (ART) is capable of 
decreasing HIV-1 viral load to levels below the limit of 
detection in many patients, the virus is not eliminated 
and interruption of ART almost always leads to a rapid 
viral rebound and progression to AIDS [24]. HIV-1 is 
capable of establishing a state of latent infection when 
activated CD4+ T-cells (the major target of HIV-1) 
become infected and then revert back to a resting mem-
ory state [25–27]. These infected resting T-cells show low 
or absent viral gene expression and provide a viral reser-
voir that is protected from immune clearance and ART 
(reviewed in [28]). Current strategies to eradicate this res-
ervoir aim at reactivating the latent proviruses by using 
various agents such as the histone deacetylase (HDAC) 
inhibitor suberoylanilide hydroxamic acid (SAHA; Vori-
nostat) [29] and the acetaldehyde dehydrogenase inhibi-
tor disulfiram [30], often combined with protein kinase 
C agonists [31]. Despite the current interest in pharma-
cological strategies to disrupt the quiescence of latent 
proviruses, the mechanism by which HIV-1 persists in 
the presence of ART is not well understood. In a recent 
study, the proximity of HIV-1 proviruses to PML NBs was 
found to correlate with the extent of HIV-1 gene expres-
sion silencing in a T cell-based HIV-1 latency model. 
Accordingly, PML degradation resulted in the activation 
of viral transcription following proviral displacement 
from PML NBs [32]. Here, we examined the involvement 
of PML in the restriction of HIV-1 in human and murine 
cells. Our results provide evidence that PML is a compo-
nent of the innate immune response to lentiviruses and 
may participate in HIV-1 gene silencing and latency.
Results
PML depletion increases the susceptibility of human T cells 
to lentivirus infection
We first investigated the effect of endogenous hPML 
depletion on HIV-1 and SIVmac infectivity in SupT1 cells, 
a human T lymphoblastoid cell line. The cells were stably 
transduced with lentiviral vectors expressing shRNAs tar-
geting all hPML isoforms or expressing an shRNA against 
luciferase as a control, and conferring puromycin resist-
ance. The untransduced cells were eliminated by puro-
mycin treatment and PML knockdown was analyzed by 
WB (Fig. 1a). The results showed that both shPML2 and 
shPML3 efficiently decreased PML expression in SupT1 
cells, whereas shPML1 had no significant effect. We next 
infected the 4 SupT1 pools with low viral doses of VSV 
protein G (VSV-G)-pseudotyped, green fluorescent pro-
tein (GFP)-expressing lentiviral vectors based on HIV-1 
strain NL43 (HIV-1NL-GFP) and simian immunodeficiency 
virus strain mac239 (SIVmac-GFP) for 2  days, followed by 
fluorescence-activated cell sorting (FACS) analysis. In 
these vectors, GFP is inserted in the Nef ORF and HIV-1 
Env expression is disrupted [33, 34]. The results showed 
that PML depletion, mediated by shPML2 and shPML3, 
increased the percentage of cells infected with HIV-1NL-
GFP (2.4-fold and 3.7-fold, respectively), whereas shPML1 
had no significant effect (Fig. 1b, left panel). Similarly, the 
permissiveness of SupT1 cells to SIVmac-GFP was increased 
4.3-fold and 3.9-fold by expression of PML shRNA2 and 
shRNA3, respectively, whereas shRNA1 had no effect 
(Fig. 1b, right panel).
GFP is routinely used as a reporter protein to study 
the activity of promoters; in particular, quantitation 
of GFP fluorescence  intensity  is a robust marker for 
expression levels, as it has been shown to directly corre-
late with mRNA levels in individual cells [35]. Recently, 
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GFP fluorescence intensity was used to analyze the Cas9 
nuclease-mediated knockout of latently integrated HIV-1 
genomes in human cells [36]. GFP expression by the HIV-
1-based vector HIV-1NL-GFP, which is used in our study, 
is under the control of a natural 5′-LTR that acts as an 
enhancer and a promoter. This allowed us to investigate 
whether hPML interferes with HIV-1 gene expression by 
quantifying GFP mean fluorescence intensity (MFI) in 
infected cells using FACS. None of the shRNAs used had 
any significant effect on the GFP MFI following infection 
Fig. 1 PML-mediated restriction of HIV-1 and SIVmac infection in SupT1 cells. a WB analysis of human SupT1 cells stably transduced with shPMLs. 
Cells were stably transduced with either the control shRNA targeting luciferase or with shRNAs targeting all hPML isoforms. PML expression levels 
were analyzed by WB using a polyclonal antibody (upper panel). The same blot was reprobed with an anti-actin antibody as a loading control. The 
graph on the right shows the ratios of PML compared to actin following densitometry analysis. b Effects of shRNA-mediated depletion of hPML on 
HIV-1 and SIVmac infectivity. The cells stably expressing shPMLs or control shRNAs were infected with HIV-1NL-GFP (left) or SIVmac-GFP (right) (MOI of 0.1). 
Two days later, the percentages of infected cells were measured by FACS. The values represent the means of three independent experiments with 
standard deviations (**P < 0.01, two-tailed Student’s t test). c Effects of shRNA-mediated depletion of hPML on HIV-1 and SIVmac LTR-driven GFP 
expression. GFP MFI values are shown for the experiments in b (ns non-significant in the two-tailed Student’s t test)
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with HIV-1NL-GFP or SIVmac-GFP (Fig.  1c). Thus, PML 
restricts the early stages of HIV-1 and SIVmac infection 
but does not affect viral gene expression in SupT1 cells.
PML confers resistance to infection of murine cells 
by lentiviruses
Restriction factors such as TRIM5α, apolipoprotein B 
mRNA editing enzyme, catalytic polypeptide-like 3G 
(APOBEC3G) and Tetherin often function in a species-
specific, virus-specific fashion [37–39]. In order to ana-
lyze the antiretroviral potential of PML in a non-human 
context, PML-KO MEFs [40] and corresponding WT 
cells were challenged with increasing doses of HIV-1NL-
GFP, SIVmac-GFP and a GFP-expressing vector based on 
equine infectious anemia virus (EIAVGFP). The percent-
age of infected (GFP-positive) cells was then measured 
by FACS. We found that MEF cells were up to 30 times 
more permissive to infection by the HIV-1 vector in the 
absence of PML (Fig.  2a). Similarly, the infectivity of 
the SIVmac and EIAV vectors was increased in PML-KO 
cells by up to 8-fold and 12-fold, respectively. This PML-
dependent restriction phenotype decreased at higher 
virus doses (Fig. 2a), suggesting the presence of a satura-
tion effect previously seen with TRIM5α [41], whereby 
large amounts of incoming retroviral cores “soak up” the 
restriction factor, resulting in attenuated or abrogated 
restriction. These data suggest that mPML is involved 
in a restriction mechanism targeting the early stages of 
infection by non-cognate lentiviruses. We used quanti-
tative PCR (qPCR) to investigate the effects of PML on 
HIV-1 DNA synthesis and nuclear import, two early 
infection steps frequently affected by previously discov-
ered restriction factors. When WT and PML-KO MEFs 
were infected with identical amounts of HIV-1NL-GFP, we 
observed ~5-fold more reverse transcribed DNA in the 
PML-KO cells (Fig.  2b). We also observed significantly 
more 2-LTR circles (a marker of nuclear import) in PML-
KO cells (Fig. 2b). However, the effect of PML on 2-LTR 
circle levels was not greater than its effect on total reverse 
transcribed DNA, suggesting that the PML-dependent 
restriction of HIV-1 in MEFs affects mainly the reverse 
transcription step, consistent with recent findings from 
other groups [22, 23].
PML promotes the down‑regulation of HIV‑1 LTR‑driven 
GFP expression in MEFs
MEF WT and PML-KO cells were infected with increas-
ing doses of HIV-1NL-GFP, as described above, followed by 
FACS. The percentage of infected cells and MFI (within 
the GFP+ population) were measured at 2 and 10  days 
post infection (dpi) (Fig.  3a, b, respectively). Perform-
ing the analyses at 10 dpi ensured that any GFP detected 
would have been expressed from integrated proviral 
DNA [42]. We found that PML knockout resulted in 
not only an increase in the percentage of GFP-express-
ing cells, but also an increase in the GFP MFI in these 
infected cells. Similar to what we observed in Fig. 2a, the 
effects of mPML knockout on viral infectivity were great-
est when a low dose of virus was used and were abrogated 
at high virus doses (>25 µl of HIV-1NL-GFP in this experi-
ment). In contrast, the effects of mPML knockout on the 
GFP MFI were relatively more constant across multiple 
doses of virus (~4-fold increase at 2 dpi, ~10-fold at 10 
dpi). At 10 dpi, however, we observed a decrease in GFP 
MFI at the two highest virus doses used (50 and 100 µl) 
in PML-KO cells, perhaps reflecting the existence of an 
additional PML-independent mechanism of inhibition. 
Altogether, results from the experiments shown in Figs. 2 
and 3 suggest that PML expression in MEFs is associated 
with at least two distinct HIV-1 restriction mechanisms; 
one takes place at early post-entry stages, whereas the 
second results in a decrease in LTR-driven gene expres-
sion. The first inhibitory mechanism can be abrogated at 
high virus doses, whereas the second is not inhibited at 
these high doses, supporting a model where these activi-
ties are independent from each other.
Overexpression of mPML restores restriction of HIV‑1 
and SIVmac in PML‑KO MEFs
Because the data reported above implicate mPML as 
a possible intrinsic defense factor against lentiviruses, 
we next examined whether its overexpression would 
restore the restriction of HIV-1 and SIVmac in PML-KO 
MEFs. For this, we cloned the mPML cDNA from MEFs 
into the murine leukemia virus (MLV)-based vector 
pMIP [43] and transduced it in both WT and PML-KO 
MEFs, together with the empty vector (EV) as control. 
Our cloning strategy allowed for the isolation of both 
main isoforms (1 and 2) of mPML, but 3/3 sequenced 
clones corresponded to mPML isoform 2, which is the 
longest of the two (GenBank accession No. KJ650238). 
After puromycin selection of transduced cell popula-
tions, mPML expression was analyzed by Western blot-
ting (WB). As shown in Fig.  4a, a band consistent with 
the expected size for mPML (110–120 kDa) was detected 
in the mPML-transduced cells, and a weaker band of 
the same size was seen in WT but not PML-KO MEFs. 
Additional bands corresponding to heavier proteins were 
also detected and could be SUMOylated forms. We then 
challenged the transduced cells with multiple doses of 
HIV-1NL-GFP (Fig. 4b, left panel) and SIVmac-GFP (Fig. 4b, 
right panel). Transduction of mPML into PML-KO MEFs 
decreased the infectivity of HIV-1NL-GFP and SIVmac-GFP 
by up to ~9-fold (Fig. 4b left panel) and ~14-fold (Fig. 4b 
right panel), respectively, similar to the levels seen in WT 
cells. In contrast to the PML-KO cells, overexpression of 
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mPML in WT MEFs had no effect on infection with the 
HIV-1 and SIVmac vectors. Like before, the magnitude 
of change in infectivity by PML knockout was greatest 
at the lowest viral doses. These results demonstrate that 
PML can inhibit the early stages of lentivirus infection in 
MEFs and suggest that endogenous mPML levels are suf-
ficient to accomplish this function.
To provide further insights into the possible  role  of 
mPML in inhibiting lentiviral gene expression, we 
also measured the GFP MFI (Fig.  4c, d). As shown in 
Fig. 2 Murine PML confers resistance to infection with lentiviruses. a Dose-dependent analysis of retrovirus infectivity. WT and PML-KO MEF cells 
were infected with increasing doses of HIV-1NL-GFP, SIVmac-GFP and EIAVGFP. The percentage of infected (GFP-expressing) cells was measured 2 days 
later by FACS. Shown is one experiment representative of ≥3 independent experiments that yielded comparable results (*P < 0.05; **P < 0.01, 
one-tailed paired Student’s t test). b Effects of PML on the early stages of HIV-1 replication. WT and PML-KO MEF cells were infected with HIV-1NL-GFP 
at a low MOI (0.01 as measured on CRFK cells, see “Methods” section). Total cellular DNA was extracted 6 and 24 h post-infection and subjected to 
qPCR of HIV-1 late reverse transcription products and 2-LTR circles. Data are shown as relative viral products levels compared to actin. An RT inhibi-
tor (nevirapine, Nev) was included as a control to show the absence of contaminating DNA. The values represent the means of three independent 
experiments with standard deviations (*P < 0.05; ***P < 0.001, two-tailed Student’s t test)
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representative FACS dot plots in Fig.  4c, overexpression 
of mPML in PML-KO MEF cells not only decreased HIV-
1NL-GFP infectivity from 76 to 14.6  % but also reduced 
the GFP MFI by 13.3-fold. In contrast, overexpression of 
mPML in WT MEF cells had only a small effect on the 
GFP MFI (less than 2-fold). Figure  4d summarizes the 
GFP MFI results obtained upon infection of mPML- or 
empty vector-transduced WT and PML-KO MEFs with 
HIV-1NL-GFP and SIVmac-GFP. We found that overexpres-
sion of mPML in PML-KO MEFs strongly decreased the 
GFP MFI following infection by HIV-1NL-GFP and SIVmac-
GFP (up to 13.3-fold and 22.3-fold, respectively). In con-
trast, overexpression of mPML in WT MEFs decreased 
GFP MFI by a much smaller magnitude following infec-
tion by HIV-1NL-GFP and SIVmac-GFP (up to 1.7-fold and 
3.1-fold, respectively). As expected, the PML-induced 
reduction in GFP MFI was not dose dependent, thereby 
distinguishing the effects of mPML on infectivity and 
GFP MFI. As an additional control, we also infected the 4 
cell pools with a GFP-expressing, “B-tropic” MLV-based 
vector [44], MLVGFP (Fig.  4d, right panel) and similarly 
measured GFP expression levels. As anticipated, we found 
that the GFP MFI did not significantly vary in response to 
expression of mPML (either endogenous or exogenous). 
Collectively, the data shown in Figs.  2, 3 and 4 demon-
strate that expression of mPML in murine cells inhibits 
both the infectivity and LTR-driven viral gene expression 
of non-murine lentiviruses.
PML‑dependent transcriptional silencing of HIV‑1 in MEFs
To further study the role of mPML in the regulation of 
the HIV-1 LTR-driven gene expression, we used SAHA, 
a HDAC inhibitor. HDACs act on histones within the 
nucleosome-bound promoter of HIV-1 to maintain 
proviral latency [45]. HDAC inhibition by SAHA leads 
to promoter expression and the escape of HIV-1 from 
transcriptional repression [29, 46]. Recently, SAHA was 
shown to affect the spatial distribution of hPML NBs 
[32]. We reasoned that if the HIV-1 LTR was repressed by 
mPML in MEFs in a fashion similar to its transcriptional 
Fig. 3 mPML knockout increases HIV-1 LTR-driven GFP expression. PML-KO and WT MEFs were infected with increasing doses of HIV-1NL-GFP and 
cells were maintained in culture for 2 days (a) or 10 days (b), followed by FACS analysis. The percentage of infected (GFP-expressing) cells and the 
mean fluorescence intensity (MFI) were measured at each time point (top and bottom panels, respectively) (**P < 0.01; ***P < 0.001; one-tailed 
paired Student’s t test)
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repression in some human lymphocyte subpopulations 
[25], then SAHA would counteract the effects of mPML 
in MEFs. We infected WT and PML-KO MEFs with 
multiple doses of HIV-1NL-GFP and maintained the cul-
tures for 10 days. The cells were then treated with either 
5  µM of SAHA or with DMSO as control for 48  h fol-
lowed by FACS analysis of the GFP MFI, performed like 
before. As shown in Fig. 5a, the levels of GFP expression 
increased by up to ~11-fold in WT cells following treat-
ment with SAHA, while a smaller increase (up to 3-fold) 
was observed in PML-KO cells. Therefore, SAHA coun-
teracts the PML-mediated reduction in LTR-driven GFP 
expression in MEF cells, consistent with transcriptional 
repression of the LTRs as the underlying mechanism. 
Fig. 4 Expression of mPML in PML-KO MEFs restores restriction of HIV-1 and SIVmac. a Western blotting (WB) analysis of mPML overexpression in 
MEFs. PML cDNA was isolated from WT cells and transduced into both WT and PML-KO MEFs. The empty vector (EV) was transduced as a control. 
mPML expression was analyzed by WB of extracts from EV-transduced MEF-WT cells (WT + EV), mPML-transduced MEF-WT cells (WT + PML), EV-
transduced PML-KO cells (KO + EV), and mPML-transduced PML-KO MEF cells (KO + PML). The WB was performed using an anti-mPML monoclonal 
antibody (upper panel) followed by an anti-actin antibody (lower panel) as a loading control. The arrow points to mPML, as judged from its expected 
size, whereas the heavier bands are presumably SUMOylated forms. The positions of the molecular size markers are indicated on the left. b Analysis 
of retrovirus infectivity in the transduced MEFs. The cells were infected with multiple doses of either HIV-1NL-GFP or SIVmac-GFP, and the percentage of 
GFP-positive cells was measured at 2 dpi by FACS (P ≤ 0.001, one-tailed paired Student’s t test for KO + PML vs. KO). c FACS plots from transduced 
MEFs infected with HIV-1NL-GFP. WT and PML-KO MEF cells transduced with either EV or mPML were infected with HIV-1NL-GFP. The percentage of 
infected cells and mean fluorescence intensities determined at 2 dpi are indicated for each plot. d Down-regulation of LTR-driven GFP expres-
sion following overexpression of mPML in PML-KO MEFs. WT and PML-KO MEFs were stably transduced with either mPML or EV, as a control, then 
infected with multiple doses of HIV-1NL-GFP (left panel), SIVmac-GFP (middle panel) or B-MLVGFP (right panel). The MFI was measured by FACS at 2 dpi 
(P < 0.01, one-tailed paired Student’s t test for KO + PML vs. KO after HIV-1NL-GFP or SIVmac-GFP infection)
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Interestingly, at the highest dose of virus used, SAHA 
had the same effect on the GFP MFI in WT and PML-KO 
cells (Fig. 5a). This observation suggests that at high virus 
doses, HIV-1 LTR-driven gene expression may addition-
ally become inhibited by a distinct mechanism independ-
ent of PML.
To insure that the inhibitory effect of PML on HIV-1 
gene expression was not specific to the GFP reporter 
gene used in previous experiments, we also analyzed the 
expression of the HIV-1 p24 capsid protein in similar set-
tings. WT and PML-KO MEFs were infected with HIV-
1NL-GFP in triplicate. 10 days later, the cells were treated 
or not with SAHA for 2  days and protein extracts were 
then analyzed by WB. As shown in Fig.  5b, c, p24 was 
barely detectable in DMSO-treated WT cells, whereas 
treatment with SAHA resulted in a 10-fold increase in 
p24 expression levels in these cells. In contrast, SAHA 
treatment caused only a 2-fold increase in p24 expression 
in PML-KO cells (Fig. 5c). Therefore, the results obtained 
in this experiment were consistent with those obtained 
for GFP.
To directly address whether the PML-dependent 
decrease in LTR-driven expression resulted from tran-
scriptional repression, we used quantitative reverse 
transcription-PCR (qRT-PCR) to analyze the abundance 
of HIV-1 mRNA in MEF cells infected with HIV-1NL-GFP 
exactly as in Fig.  5b. Levels of HIV-1 mRNA (analyzed 
using primers specific to the GFP coding sequence) were 
less than 1 copy per ng of total RNA in WT MEFs, but 
were 11.7 times higher in PML-KO cells (Fig.  5d). In 
response to the treatment of WT cells with SAHA, we 
observed a 15-fold increase in the levels of viral mRNA, 
compared to an increase of only 3.5-fold in the PML-KO 
cells. A second qPCR analysis was performed, this time 
normalized to actin transcription level (see Additional 
file  1). The results were consistent with those shown in 
Fig.  5d, as HIV-1 transcription was found to be 13.3-
fold higher in the absence of mPML and SAHA specifi-
cally rescued HIV-1 transcription in WT MEFs. Taken 
Fig. 5 SAHA counteracts the PML-dependent inhibition of HIV-1 
gene expression. a Effects of SAHA on HIV-1 LTR-driven GFP expres-
sion. PML-KO and WT MEFs were infected with increasing doses of 
HIV-1NL-GFP. Ten days later, the cells were treated with 5 µM SAHA 
or with DMSO for 48 h and the MFI was then measured by FACS 
(P = 0.0001, one-tailed paired Student’s t test for SAHA vs. DMSO 
treatment in WT cells). b Analysis of HIV-1 p24 expression levels. 
PML-KO and WT MEFs were infected in triplicate with HIV-1NL-GFP 
at a CRFK MOI of 0.1 and then treated with either SAHA or DMSO 
at 10 dpi. Cellular lysates were prepared 48 h later and analyzed by 
WB using an anti-p24 antibody. Uninfected extracts were used as a 
negative control and actin was analyzed as a loading control. c The 
p24 and actin bands in the WB analysis shown in b were quantified 
by densitometry. The values represent the means of p24/actin ratios 
from the three data points for each condition with standard devia-
tions (*P < 0.05; **P < 0.01, two-tailed Student’s t test). d qRT-PCR 
analysis of HIV-1 transcription. WT or PML-KO MEFs were infected with 
HIV-1NL-GFP in triplicate. Ten days after infection, the cells were treated 
with either DMSO or SAHA for 48 h. Total RNA was purified from 
the cells and the level of GFP transcript was quantified by qRT-PCR. 
Total RNA from uninfected cells was used as a negative control. The 
values represent the means of three independent experiments with 
standard deviations (*P < 0.05; **P < 0.01, two-tailed Student’s t test). 
ND not detected
◂
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together, these results provide strong evidence that 
mPML interferes with the HIV-1 transcription in MEFs.
mPML‑mediated restriction of lentiviruses does not require 
IFN‑I, but mPML contributes to IFN‑I‑induced antiviral 
responses
The hPML expression levels can be altered during infec-
tion with some viruses, such as HSV-1, HCMV and 
Epstein–Barr virus (EBV) [47]. Interestingly, we observed 
a significant increase in the levels of mPML expression 
in response to infection of MEFs with the HIV-1NL-GFP, 
SIVmac-GFP, and B-MLVGFP vectors (Fig.  6a), suggesting 
an interferon-dependent mechanism. Accordingly, the 
expression of PML is known to be increased in response 
to both type I and II IFNs [9, 48]. IFNs might be relevant 
to the observed HIV-1 restriction phenotype in MEFs in 
two ways. First, IFN treatment-mediated antiviral activi-
ties might be dependent on PML. Second, PML could 
indirectly interfere with HIV-1 infection and/or tran-
scription by upregulating the production of type I IFN. 
To test the latter hypothesis, IFN-induced signaling in 
MEFs was prevented by using a blocking antibody against 
the mouse IFN-alpha/beta receptor subunit 1 (IFNAR-
1) [49]. The efficacy of this antibody was determined by 
treating WT MEFs with murine IFN-β in the presence 
or absence of the blocking antibody and then measur-
ing the levels of mPML expression by WB (Fig. 6b). The 
results show that, as expected, PML levels were greatly 
increased by IFN-β treatment, whereas treatment with 
the anti-IFNAR-1 antibody abrogated this effect in a 
dose-dependent fashion. Next, WT and PML-KO MEFs 
were treated with the blocking antibody (650  ng per 
20,000 cells) prior to infection with increasing doses of 
HIV-1 (Fig.  6c). Compared with control untreated cells, 
inhibition of IFN-induced signal transduction did not 
modulate HIV-1 infectivity (Fig. 6c, left panel) nor HIV-1 
LTR-driven GFP expression levels (Fig.  6c, right panel) 
in either WT or PML-KO MEFs. These results indicate 
that PML-mediated restriction of HIV-1 in MEFs does 
not require activation of IFN-mediated pathways, even 
though PML itself is upregulated by IFNs.
To test whether PML is important for IFN-mediated 
antiviral activity, we treated both WT and PML-KO 
MEFs with IFN-β for 16  h, then challenged them with 
HIV-1NL-GFP. As shown in Fig. 6d (left panel), treatment 
with IFN-β led to a 20-fold reduction in the percentage 
of infected cells in the presence of PML compared to only 
a 5-fold decrease in infectivity in PML-KO cells. How-
ever, IFN-β treatment did not modify the GFP MFI in 
either WT or PML-KO cells (Fig. 6d, right panel). To ana-
lyze further the importance of PML in IFN-β-mediated 
inhibition of HIV-1, we treated WT and PML-KO cells 
with murine IFN-α or IFN-β and then infected them 
with increasing doses of HIV-1NL-GFP. We found that 
IFN treatment reduced the infectivity of HIV-1 by up to 
~100-fold at low virus doses in WT cells. However, the 
inhibitory effect of IFNs was significantly more modest 
(up to ~10-fold) in PML-KO cells (Fig. 6e). Therefore, our 
data support a model where type I IFNs inhibit HIV-1 
through mechanisms that partially involve the PML-
mediated inhibition of early replication stages but are not 
relevant to the inhibition of LTR-driven gene expression. 
Thus, PML-mediated antilentiviral functions can be both 
induced and constitutive.
Human PML expression induces restriction of HIV‑1 
and SIVmac in MEFs
To investigate the isoform specificity and the cellular 
context specificity of the restriction of HIV-1 by hPML, 
we expressed several hPML isoforms in PML-KO MEFs. 
We stably transduced FLAG-tagged versions of all six 
nuclear hPML isoforms (isoforms I to VI) [50] individu-
ally into these cells. The cells were selected in puromy-
cin to eliminate untransduced cells. Immunofluorescence 
staining of the transduced MEF cells using an anti-FLAG 
antibody indicated that the different hPML isoforms 
were expressed in nuclei (Fig.  7a), though some cyto-
plasmic staining was detected for PML-V. WB analyses 
confirmed that all isoforms were expressed, albeit at vari-
ous levels, with isoforms III, IV and V being expressed 
at apparently lower levels (see Additional file  2). The 
cells were then infected with increasing doses of HIV-
1NL-GFP or SIVmac-GFP (Fig. 7b). HIV-1 was ~5- to 10-fold 
less infectious in PML-KO MEFs expressing hPML-I, II, 
IV and VI, compared with the empty vector-transduced 
control cells. PML-V had a more modest effect and PML-
III did not impede HIV-1 infection (Fig.  7b, left panel). 
Transduction of hPML-I, II, IV, and VI in PML-KO MEFs 
also reduced the infectivity of SIVmac-GFP, by up to 44-fold 
(Fig.  7b, right panel). Similar to HIV-1NL-GFP, SIVmac-
GFP infectivity was modestly inhibited by hPML-V and 
was not affected by hPML-III. HIV-1 LTR-driven gene 
expression was assessed by measuring the GFP MFI in 
the infected cells. We observed that hPML-I, II, IV, and 
VI caused a reduction in GFP levels in MEFs infected 
with HIV-1NL-GFP or SIVmac-GFP, while hPML-III and V 
had no effect (Fig. 7c). These data show that hPML can 
restrict HIV-1 and SIVmac in MEFs but in an isoform-
specific fashion. In addition, hPML-V decreased HIV-1 
infectivity but had no effect on HIV-1 LTR-driven GFP 
expression levels, implying that these two restriction 
mechanisms are genetically separable.
We next tested whether SAHA treatment would spe-
cifically rescue HIV-1 LTR-driven GFP expression in 
MEF cells expressing human PML isoforms. PML-KO 
MEFs stably expressing hPML isoforms I to VI were 
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infected with low doses of HIV-1NL-GFP and kept in cul-
ture for 10 days. The cells were then treated with either 
5 µM of SAHA or with DMSO as a control for 48 h, fol-
lowed by FACS analysis. We observed that expression of 
hPML isoforms I, II and VI led to a decrease in HIV-1NL-
GFP infectivity, although the magnitude of this inhibition 
was slightly smaller than what was observed 2 days post-
infection. hPML-IV and V did not significantly decrease 
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HIV-1NL-GFP infectivity, as seen at this time-point (Fig. 7d, 
left panel), perhaps due to the fact that these human iso-
forms delayed infection with HIV-1 rather than disrupt-
ing it entirely. hPML-I, II, III and VI caused a reduction 
in GFP MFI in these conditions (Fig.  7d, right panel), 
but this effect was also smaller than we had observed at 
2 days post-infection (Fig. 7c). As expected, SAHA treat-
ment had no significant effect on the infectivity of HIV-
1NL-GFP in PML-KO MEFs expressing the various hPML 
isoforms (Fig.  7d, left panel). SAHA slightly increased 
(1.9-fold) the GFP MFI in the control cells (Fig. 7d, right 
panel), a result similar to what we had observed before 
(Fig.  5). The effect of SAHA was significantly greater in 
cells stably expressing hPML-I, III and VI (Fig. 7d, right 
panel), suggesting that the mechanism of inhibition of 
GFP expression by these isoforms was transcriptional 
silencing, similar to what we had demonstrated with 
mPML. Taken together, these data suggest that hPML 
can mediate the two inhibitory phenotypes also observed 
with mPML, although in an isoform-specific, cellular 
context-specific manner.
Discussion
The results from this study show that PML can inter-
fere with at least two distinct steps in the replication of 
HIV-1 and other lentiviruses. The first block to replica-
tion occurs at early post-entry stages and was seen in 
both MEF and SupT1 cells, although the magnitude of 
the restriction was significantly higher in the murine 
cells. The existence of an early post-entry block to HIV-1 
replication in murine cells has long been known [51, 52]. 
This restriction of HIV-1 infection was seen in all murine 
cell types analyzed by these investigators, although it 
was stronger in lymphocytes compared to fibroblasts 
[53]. On the basis of viral DNA analyses, the block was 
found to occur prior to integration [53–55], consist-
ent with recent results from other groups [22, 23]. Here 
we show that in addition to HIV-1, the early post-entry 
replication of two other lentiviruses, SIVmac and EIAV, is 
restricted in murine MEFs. Our results indicate that PML 
is required for this early phase of restriction to occur. 
Another team recently reported that the PML body com-
ponent Daxx was involved in the PML-mediated inhibi-
tion of HIV-1 [23], though this finding was contradicted 
in a report from another group [22]. We find that the 
PML-dependent restriction of early-stage HIV-1 infec-
tion was increased by treatment with IFN-α or IFN-β, 
which suggests that PML is relevant to the intrinsic cel-
lular defenses against retroviral infections. Type I IFN 
treatment increased expression of mPML itself (Fig.  6), 
yet mPML overexpression was not sufficient to increase 
the restriction of incoming HIV-1 or SIVmac in MEFs 
(Fig.  4). These various observations are consistent with 
a model thereby IFN-I inhibits HIV-1 in mouse cells by 
increasing the expression of a restriction factor that acts 
downstream of PML and directly targets incoming HIV-
1. Along these lines, restriction of HIV-1 appeared to 
be saturable in several of our experiments, supporting a 
model where an antiviral effector is present in limiting 
concentrations, which is not consistent with PML being 
this effector. Also in support of an indirect effect of PML 
is the fact that HIV-1 infection of MEFs was inhibited 
at reverse transcription, a step that takes place in the 
cytoplasm while PML is predominantly nuclear. Taken 
together, these observations suggest that PML promotes 
the restriction of multiple lentiviruses by activating a 
downstream effector whose identity and viral target(s) 
remain to be determined. Interestingly, PML was recently 
found to be involved in the transcriptional activation of 
interferon-stimulated genes following treatment with 
IFN-I [56], supporting the idea that PML plays an activat-
ing role upstream of innate immune effectors.
In addition to its effects on early stage viral replication, 
PML also caused transcriptional silencing of HIV-1 in 
MEFs, a result consistent with previous observations that 
HIV-1 transcription was low in murine cells, even in the 
presence of human cyclin T1 (hCycT1) [57]. Unlike the 
restriction of early stages of replication, the repression of 
(See figure on previous page.) 
Fig. 6 HIV-1 restriction by mPML does not require a type I IFN-induced antiviral state, but efficient IFN-induced inhibition of HIV-1 in MEFs requires 
PML. a WB analysis of infection-induced up-regulation of PML in MEFs. WT MEF cells were infected with HIV-1NL-GFP, SIVmac-GFP, or B-MLVGFP at an 
MOI of 1. Protein extracts were analyzed by WB at 6 or 24 h post infection, along with a no-infection control, using an anti-mPML monoclonal anti-
body (upper panel). Actin was analyzed as a loading control. b Expression of mPML was analyzed in WT MEFs left untreated (Ctrl), treated with IFN-β 
alone, or treated with a blocking antibody against IFNAR-1 at two different doses to block IFN-β-induced signal transduction prior to IFN-β treat-
ment. mPML was detected using a monoclonal antibody (upper panel). Actin was analyzed as a loading control. c Blocking the IFN-I receptor does 
not alter HIV-1NL-GFP restriction by PML. PML-KO and WT MEFs were treated with the anti-IFNAR-1 antibody, or with PBS as a control, and were then 
infected with increasing doses of HIV-1NL-GFP. The percentage of infected cells (left panel) and GFP MFI (right panel) were assessed 2 days later by 
FACS. d The effects of IFN-I and PML on the antiviral state. PML-KO and WT MEFs were treated with IFN-β for 16 h prior to infection with HIV-1NL-GFP. 
The percentage of infected cells (left panel) and GFP MFI (right panel) were assessed 2 days later by FACS. The values represent the means of three 
independent infections with standard deviations (**P < 0.01, two-tailed Student’s t test; ns non-significant). e Virus dose-dependent analysis of the 
role of PML in IFN-induced HIV-1 restriction. WT and PML-KO MEFs were treated with either IFN-α (500 U/ml) or IFN-β (100 U/ml) for 16 h, followed 
by infection with increasing doses of HIV-1NL-GFP. The percentage of infected cells was assessed 2 days later by FACS
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HIV-1 gene expression was not enhanced by IFN-I treat-
ment. Therefore, although both inhibitory mechanisms 
are dependent upon the presence of PML, they are dif-
ferentially regulated. We found no evidence that hPML 
repressed HIV-1 LTR-driven gene expression in SupT1 
cells. However, transfer of some hPML isoforms (hPML-I, 
II, IV and VI and to a lesser extent hPML-V) in PML-KO 
MEFs fully reconstituted the restriction activities, sup-
porting a conserved role for mPML and hPML. This dis-
crepancy may result from the fact that the establishment 
of latency in human cells may be rare and may occur only 
in specific conditions, whereas the HIV-1 promoter is con-
stitutively repressed in murine cells. Recently, two differ-
ent teams used cell lines belonging to the “J-Lat” series, 
which are human T cell lines containing integrated but 
transcriptionally silent copies of an HIV-1-derived vector, 
to investigate whether PML and PML bodies have a role in 
latency. Both teams found that latent HIV-1 could be reac-
tivated by treatment with the PML inhibitor arsenic triox-
ide (As2O3) [32, 58]. Lusic and collaborators also observed 
that PML depletion similarly reactivated HIV-1 in the J-Lat 
9.2 clone [32]. These results show that PML is required for 
the maintenance of transcriptional latency in these mod-
els, but they do not address the question of whether it is 
involved in the establishment of latency. MEFs and possi-
bly other murine cell types in which HIV-1 transcription 
is constitutively repressed may provide valuable investiga-
tory tools to identify the factors controlling the establish-
ment and maintenance of viral latency and persistence.
As2O3 has been shown to interfere with several retro-
viral restriction pathways over recent years, including 
TRIM5α [20, 59], TRIMCyp [60], APOBEC3G [61], Lv4 
[62] and possibly SAMHD1 [63]. As2O3 is unlikely to 
directly inhibit those various restriction effectors. There-
fore, the most straightforward explanation is that it acts 
upstream, by interacting with a factor that controls the 
global antiviral state of the cell. Clues that PML might 
be this factor come from imaging and biochemical stud-
ies that used fluorescent and biotin-labeled analogs of 
As2O3. These studies strongly suggested that PML was 
the major and perhaps the sole cellular target for this 
drug [64, 65]. As2O3 promotes PML oligomerization, 
resulting in increased SUMOylation and ubiquitination, 
followed by proteasome-dependent degradation [64]. The 
picture emerging from these and other studies [56] is that 
PML upregulates antiretroviral effectors that target viral 
replication at several steps. Changes in the expression 
patterns of these downstream effectors might explain 
the cellular context specificity observed for the effects of 
PML expression on HIV-1.
Conclusions
Taken together, our observations suggest that PML 
broadly upregulates the activity of innate antiviral effec-
tors, through mechanisms that are yet to be dissected. It 
has been suggested that the PML inhibitor As2O3 could 
be tested as a pharmacological agent to counter HIV-1 
latency in humans [32, 58]. However, this study and 
previous ones [20, 23] show that targeting PML might 
enhance the early stages of HIV-1 replication by remov-
ing PML-controlled antiviral activities. Thus, As2O3 and 
other compounds targeting PML likely involve a trade-
off between inhibition of latency and inhibition of innate 
immune mechanisms. Our results are also relevant to the 
development of murine models for HIV-1. Despite multi-
ple attempts at introducing key human positive factors in 
murine cells, such as hCD4, hCCR5, hCycT1 or hCRM1 
[64, 66, 67], murine cells remain non-permissive to HIV-
1. Removing the endogenous mPML in the context of 
murine cells expressing key human factors might support 
HIV-1 propagation. The availability of PML knockout 
mice for crossing experiments [40] might finally open the 




Immortalized PML-KO and WT MEFs were a gener-
ous gift from Pier P. Pandolfi [40]. Crandell-Rees feline 
kidney (CRFK), human embryonic kidney (HEK) 293T 
(See figure on previous page.) 
Fig. 7 Expression of hPML isoforms in MEFs restricts HIV-1 and SIVmac. a Immunofluorescence staining of hPML in PML-KO MEFs stably transduced 
with FLAG-tagged hPML isoforms I to VI. Images are representative of multiple observations. hPMLs were stained with an anti-FLAG antibody (green) 
and nuclear DNA was stained using Hoechst 33342 (blue). Scale bar 5 µm. b Effects of hPML isoforms on HIV-1 and SIVmac infectivity. PML-KO cells 
transduced with individual hPML isoforms were infected with increasing doses of HIV-1NL-GFP (left) or SIVmac-GFP (right). The percentage of infected 
cells was measured 2 days later by FACS. c Effects of hPML isoforms on HIV-1 and SIVmac LTR-driven GFP expression. GFP MFI values are shown for 
the experiments in b. d Effects of SAHA on hPML-dependent restriction of HIV-1 infectivity and LTR-driven GFP expression. MEF cells transduced 
with the individual hPML isoforms were infected with HIV-1NL-GFP at a CRFK MOI of 0.1. Ten days later, the cells were treated with either DMSO (no 
drug control) or SAHA for 48 h, followed by FACS. The percentage of infected cells (left panel) and GFP MFI (right panel) were assessed. The values 
represent the means of three independent experiments with standard deviations. The SAHA-dependent fold-increase in GFP MFI was compared 
between cells transduced with individual hPML isoforms and those transduced with the empty vector (Ctrl) using the two-tailed Student’s t test. 
The calculated P values are indicated on the graph. ns non-significant
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and MEF cells were maintained in Dulbecco’s modi-
fied Eagle’s medium (DMEM; HyClone, Thermo Scien-
tific, USA). SupT1 cells were maintained in RPMI 1640 
(HyClone). All culture media were supplemented with 
10 % fetal bovine serum (FBS) and penicillin/streptomy-
cin (HyClone).
Plasmids, transfections and transductions
To transduce mPML using a retroviral vector, total RNA 
was extracted from WT MEF cells using Trizol (Invit-
rogen, Carlsbad, CA) according to the manufacturer’s 
instructions. First-strand cDNA synthesis was conducted 
using 2  µg of total RNA, random hexamers and the 
SuperScript III first-strand synthesis kit (Invitrogen) fol-
lowing treatment with DNase I (NEB), as described in 
the manufacturer’s protocol. Mouse PML (mPML) cDNA 
was then amplified by PCR using the oligodeoxynucleo-
tide (ODN) primers whose sequences are provided in 
the Additional file  3. The resulting 2.65-kb cDNA frag-
ment was cut with BamHI-MfeI and then inserted into 
the MLV-based retroviral vector pMIP [43], and cut with 
BglII and EcoRI, yielding pMIP-mPML. The cloned PML 
cDNA was sequenced and determined to be a variant of 
isoform 2 (GenBank accession No. KJ650238). To trans-
duce N-terminally FLAG-tagged versions of hPML iso-
forms I to VI using a retroviral vector, individual isoforms 
were PCR amplified from the corresponding pLNGY-
hPML constructs generously provided by R. D. Everett 
[50], using the ODNs shown in Table A1, and cloned 
into pMIP, which had been cut with BglII-EcoRI, yielding 
pMIP-hPML-I to -VI.
Retroviral vectors expressing mPML or hPML were 
prepared by cotransfection of 293T cells plated at 70  % 
confluency in 10  cm dishes with 10  µg of pMIP-m(h)
PMLs together with 5  µg of pMD-G [68] and 10  µg of 
pCl-Eco [69] using polyethylenimine (PEI; Polyscience, 
Niles, IL). Virus-containing supernatants were collected 
2 days later and clarified by low-speed centrifugation, as 
described previously [20, 70]. Stable mouse or human 
PML-expressing MEFs were obtained by spinfection of 
2  ×  105  cells with 2  ml of retroviral vector-containing 
supernatants for 50 min at 400×g in the presence of 8 µg/
ml polybrene (Sigma-Aldrich, MO, USA) [71] and fol-
lowed by a 24 h incubation at 37 °C. In order to eliminate 
the non-transduced cells, puromycin (Calbiochem, CA, 
USA) was then added to the cultures at a final concen-
tration of 2 µg/ml for 5 days. The relevant “empty” (non-
PML-expressing) vector was transduced as a control in 
all experiments.
To produce GFP-expressing retroviral vectors, 293T 
cells were seeded in 10  cm culture dishes and tran-
siently cotransfected as described above. The plasmids 
used were as follows: pMD-G, pCNCG and pCIG3-B 
to produce B-MLVGFP [72, 73]; pMD-G and pNL-GFP 
to produce HIV-1NL-GFP [20, 33]; pMD-G and pSIV-
mac239GFP to produce SIVmac-GFP [34]; or pONY3.1, 
pONY8.0 and pMD-G to produce EIAVGFP [74]. The 
supernatants were replaced with fresh medium after 6 h 
and the retroviruses were harvested 24 h later. The retro-
viruses were clarified by centrifugation at 3000 rpm and 
stored in aliquots at −80 °C. The viral stocks were titered 
by serial dilution on CRFK cells.
RNA interference
ODNs were designed to create pAPM-based, shRNA-
expressing constructs targeting hPML, as described 
previously [75, 76]. The shRNAs expressed targeted 
the following sequences, present in all hPML iso-
forms: shPML1, AAGATGCAGCTGTATCCAAGA; 
shPML2, GCAAGACCAACAACATCTTCT; shPML3, 
GCACACGCTGTGCTCAGGATG. The full sequences 
of the ODNs used to generate these constructs are pro-
vided in Additional file 3. SupT1 cells were stably trans-
duced with shRNAs targeting hPML or Luciferase as 
a control via lentiviral gene transfer. Briefly, lentiviral 
vectors were prepared by cotransfection of HEK293T 
cells with 10  µg of either pAPM-shLuc [76] or pAPM-
shPML1-3, together with 5  µg of pMDG and 10  µg of 
pΔR8.9 [68], as described above. The viral supernatants 
were used for transduction of shPMLs into SupT1 cells, 
as detailed above. Stably transduced cells were selected 
by addition of 5 µg/ml puromycin to the medium at 2 dpi 
and for 5 days.
Antibodies and WB analyses
The cells were lysed at 4  °C in RIPA lysis buffer (1  % 
NP40, 0.5  % deoxycholate, 0.1  % SDS, 150  mM NaCl, 
50 mM Tris–HCl pH 8.0). The lysates were subjected to 
SDS–polyacrylamide gel electrophoresis, followed by 
WB analysis using mouse anti-mPML mAb (36-1-104, 
Enzo life sciences, NY, USA), rabbit polyclonal anti-
hPML (H-238, Santa Cruz, TX, USA), anti-FLAG (Cell 
Signaling, MA, USA), or anti-β-actin antibody (Sigma, 
MI, USA). The p24 capsid protein of HIV-1 (CA, p24) 
was detected using a mouse monoclonal antibody (clone 
183, AIDS Research and Reference Reagent Program Cat. 
No. 3537).
Immunofluorescence microscopy
PML-KO cells stably transduced with FLAG-tagged 
hPML-I to VI isoforms or WT MEFs were seeded on 
glass coverslips placed in 3.5-cm wells. After 24  h, the 
cells were permeabilized and fixed for 10 min in Triton 
X-100/4 % formaldehyde at room temperature (RT), fol-
lowed by four washes with PBS. The cells were then 
treated with 10 % goat serum (Sigma) for 30 min at RT 
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followed by 4  h of incubation with antibodies against 
FLAG (Sigma, 1:150) or hPML (Santa Cruz, 1:150) or 
mPML (Enzo Life Sciences, 1:150) in 10  % goat serum 
at RT. They were then washed four times with PBS 
and fluorescently stained with Alexa Fluor 488-conju-
gated goat anti-mouse (Molecular Probes, Eugene, OR) 
diluted 1:100 in 10 % goat serum for 1 h at RT. The cells 
were then washed 4 times with PBS before mounting in 
Vectashield (Vector Laboratories, Peterborough, UK). 
Hoechst 33342 (0.8 μg/ml; Molecular Probes) was added 
along with the penultimate PBS wash to reveal DNA. 
Z-stacks were acquired on an AxioObserver Microscope 
(Carl Zeiss Canada, Toronto, ON) equipped with the 
Apotome module, and the median optical slice of each 
Z-stack was analyzed.
Pharmacological treatments
SAHA (Sigma-Aldrich) was resuspended in DMSO and 
used at a final concentration of 5  µM for 48  h prior to 
flow cytometric analysis. Recombinant murine IFN-α 
(11200-2) and IFN-β (12405-1) were obtained from PBL 
Interferon Source (NJ, USA) and added to the cells 16 h 
prior to infection with retroviruses. 24 h after infection, 
the supernatants were replaced with fresh IFN-contain-
ing medium. To block the extracellular domain of the 
IFN-I receptor in MEFs, the cells were treated with puri-
fied anti-mouse IFNAR-1 antibody (MAR1-5A3, BioLe-
gend, UK), at a concentration of 650 ng per 20,000 cells, 
1 h prior to infection with HIV-1NL-GFP. Where applica-
ble, the supernatants were replaced with fresh drug-con-
taining medium 24 h after infection.
Viral challenges and flow cytometric analysis
The cells were seeded into 24-well plates at 2 × 104 cells/
well (MEF) or 1 × 105 cells/well (SupT1) and infected the 
following day with GFP-expressing retroviral vectors. 
MEF cells were trypsinized at 2 dpi and fixed in 3 % for-
maldehyde (Fisher Scientific, MA, USA). The percentage 
of GFP-positive cells and MFI were then determined by 
analyzing 104 cells on a FC500 MPL cytometer (Beckman 
Coulter, CA, USA) using the CXP Software (Beckman 
Coulter). MFI analysis was restricted to the GFP-positive 
cells.
Quantitative real‑time PCR
The late RT products, 2-LTR circles, and HIV-1NL-GFP 
mRNA expression levels in infected cells were meas-
ured by either qPCR or qRT-PCR using the Stratagene 
Mx3000P system (Agilent, CA, USA). The cells were 
plated in 12-well plates at 3 × 105 cells/well and infected 
with HIV-1NL-GFP. The retrovirus was pretreated with 
20 U/ml DNase I (NEB) for 1  h at 37  °C and control 
infections were performed in the presence of 80  µM 
nevirapine (Sigma), as described previously, to demon-
strate the absence of carry-over contaminating plasmid 
DNA [77]. Total cellular DNA was collected after 6 h of 
infection (late RT products) or 6 h of infection followed 
by 18 h incubation in virus-free medium (2-LTR-circles) 
using the QIAamp DNA mini kit (Qiagen, CA, USA). 
Sequence data for the ODNs used in the PCR reactions 
(GFP forward and reverse, 2-LTR circles forward and 
reverse, actin forward and reverse) is provided in Addi-
tional file 3. The reactions contained 1x SensiFast SYBR 
Lo-ROX mix (Bioline, UK), 400 nM forward and reverse 
primers, and 5 µl template (150–400 ng) in 20 µl final vol-
ume. After 3 min incubation at 95 °C, 40 cycles of ampli-
fication were performed as follows: 5  s at 95  °C, 10  s at 
62 °C (GFP) or 65 °C (2-LTR), 15 s at 72 °C.
For qRT-PCR, total RNAs were purified from infected 
or uninfected MEFs using the AllPrep RNA/Protein kit 
(Qiagen). Reverse transcription of 200  ng of each RNA 
sample followed by real time PCR were performed in a 
final volume of 20 µl using the SensiFAST SYBR Lo-ROX 
One-Step kit (Bioline) according to the manufacturer’s 
instructions. The primer sets to detect GFP and actin in 
the PCR reactions were as mentioned above. The reac-
tion conditions were: 48 °C for 30 min, 95 °C for 10 min, 
40 cycles of amplification: 95 °C for 15 s, 60 °C for 30 s. 
Primers were validated by performing a standard curve 
and through dissociation curves analysis. Plasmid copy 
numbers dilutions ranging from 5.5  ×  105 down to 14 
were used for the GFP standard curve. Results were 
then analyzed with the MxPro software (Agilent). Abso-
lute counts were determined using the equation of the 
standard curve log(y) = ax + b where copy number was 
10((Ctsample−b)/−a).
Each PCR was performed in duplicate and the thresh-
old cycle (Ct) was determined using the MxPro software 
(Agilent). In each experiment, a standard curve was run 
in duplicate, ranging from 300 to 3 ×  105  copies plus a 
no-template control. The levels of HIV-1 transcript were 
normalized to those of GAPDH, which was quantified in 
parallel as an endogenous control.
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